Cargando…

Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery

BACKGROUND: Oral administration offered a painless way and improved compliance for diabetics. However, the emerging GLP-1 analog peptide drugs for diabetes primarily rely on the injection route, and the development of oral dosage forms was hampered by the low oral bioavailability due to the structur...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Xiaoyan, Qian, Kang, Xu, Mengjiao, Chen, Yi, Wang, Hao, Pan, Ting, Wang, Zhengyi, Yao, Ping, Lin, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843898/
https://www.ncbi.nlm.nih.gov/pubmed/36647125
http://dx.doi.org/10.1186/s12951-022-01743-9
_version_ 1784870499571990528
author Bao, Xiaoyan
Qian, Kang
Xu, Mengjiao
Chen, Yi
Wang, Hao
Pan, Ting
Wang, Zhengyi
Yao, Ping
Lin, Li
author_facet Bao, Xiaoyan
Qian, Kang
Xu, Mengjiao
Chen, Yi
Wang, Hao
Pan, Ting
Wang, Zhengyi
Yao, Ping
Lin, Li
author_sort Bao, Xiaoyan
collection PubMed
description BACKGROUND: Oral administration offered a painless way and improved compliance for diabetics. However, the emerging GLP-1 analog peptide drugs for diabetes primarily rely on the injection route, and the development of oral dosage forms was hampered by the low oral bioavailability due to the structural vulnerability to digestive enzymes and molecule impermeability in the gastrointestinal tract. RESULTS: In this study, the non-covalent interaction between cholic acid (CA) and liraglutide (LIRA) was found and theoretically explained by molecular docking simulation. Formation of this physical complex of liraglutide and cholic acid (LIRA/CA Complex) reduced the self-aggregation of LIRA and accelerated intestinal epithelium penetration. By the anti-solvent method, LIRA/CA Complex was loaded into zein/rhamnolipids nanoparticles (LIRA/CA@Zein/RLs) with a loading efficiency of 76.8%. LIRA was protected from fast enzymatic degradation by the hydrophobic zein component. Meanwhile, Rhamnolipids, a glycolipid with surface activity, promoted endocytosis while also stabilizing the nanoparticles. The two components worked synergistically to ensure the delivery of LIRA/CA Complex to intestinal villi and improved oral absorption without disrupting tight junctions. LIRA/CA@Zein/RLs demonstrated a considerable intestinal epithelium absorption in mouse gastrointestinal section and a retention in vivo over 24 h, resulting in a significant and long-lasting hypoglycemic effect in Type 2 diabetes mice. CONCLUSION: This study provided a promising oral delivery approach for LIRA and exhibited the potential for further translation into clinical application. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01743-9.
format Online
Article
Text
id pubmed-9843898
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98438982023-01-18 Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery Bao, Xiaoyan Qian, Kang Xu, Mengjiao Chen, Yi Wang, Hao Pan, Ting Wang, Zhengyi Yao, Ping Lin, Li J Nanobiotechnology Research BACKGROUND: Oral administration offered a painless way and improved compliance for diabetics. However, the emerging GLP-1 analog peptide drugs for diabetes primarily rely on the injection route, and the development of oral dosage forms was hampered by the low oral bioavailability due to the structural vulnerability to digestive enzymes and molecule impermeability in the gastrointestinal tract. RESULTS: In this study, the non-covalent interaction between cholic acid (CA) and liraglutide (LIRA) was found and theoretically explained by molecular docking simulation. Formation of this physical complex of liraglutide and cholic acid (LIRA/CA Complex) reduced the self-aggregation of LIRA and accelerated intestinal epithelium penetration. By the anti-solvent method, LIRA/CA Complex was loaded into zein/rhamnolipids nanoparticles (LIRA/CA@Zein/RLs) with a loading efficiency of 76.8%. LIRA was protected from fast enzymatic degradation by the hydrophobic zein component. Meanwhile, Rhamnolipids, a glycolipid with surface activity, promoted endocytosis while also stabilizing the nanoparticles. The two components worked synergistically to ensure the delivery of LIRA/CA Complex to intestinal villi and improved oral absorption without disrupting tight junctions. LIRA/CA@Zein/RLs demonstrated a considerable intestinal epithelium absorption in mouse gastrointestinal section and a retention in vivo over 24 h, resulting in a significant and long-lasting hypoglycemic effect in Type 2 diabetes mice. CONCLUSION: This study provided a promising oral delivery approach for LIRA and exhibited the potential for further translation into clinical application. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01743-9. BioMed Central 2023-01-16 /pmc/articles/PMC9843898/ /pubmed/36647125 http://dx.doi.org/10.1186/s12951-022-01743-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bao, Xiaoyan
Qian, Kang
Xu, Mengjiao
Chen, Yi
Wang, Hao
Pan, Ting
Wang, Zhengyi
Yao, Ping
Lin, Li
Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery
title Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery
title_full Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery
title_fullStr Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery
title_full_unstemmed Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery
title_short Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery
title_sort intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843898/
https://www.ncbi.nlm.nih.gov/pubmed/36647125
http://dx.doi.org/10.1186/s12951-022-01743-9
work_keys_str_mv AT baoxiaoyan intestinalepitheliumpenetrationofliraglutideviacholicacidprecomplexationandzeinrhamnolipidsnanocompositedelivery
AT qiankang intestinalepitheliumpenetrationofliraglutideviacholicacidprecomplexationandzeinrhamnolipidsnanocompositedelivery
AT xumengjiao intestinalepitheliumpenetrationofliraglutideviacholicacidprecomplexationandzeinrhamnolipidsnanocompositedelivery
AT chenyi intestinalepitheliumpenetrationofliraglutideviacholicacidprecomplexationandzeinrhamnolipidsnanocompositedelivery
AT wanghao intestinalepitheliumpenetrationofliraglutideviacholicacidprecomplexationandzeinrhamnolipidsnanocompositedelivery
AT panting intestinalepitheliumpenetrationofliraglutideviacholicacidprecomplexationandzeinrhamnolipidsnanocompositedelivery
AT wangzhengyi intestinalepitheliumpenetrationofliraglutideviacholicacidprecomplexationandzeinrhamnolipidsnanocompositedelivery
AT yaoping intestinalepitheliumpenetrationofliraglutideviacholicacidprecomplexationandzeinrhamnolipidsnanocompositedelivery
AT linli intestinalepitheliumpenetrationofliraglutideviacholicacidprecomplexationandzeinrhamnolipidsnanocompositedelivery